Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 12.98% | 75.14% | 73.85% | 58.23% | 32.59% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 21.96% | 25.51% | 17.95% | 30.63% | 58.28% |
Operating Income | -21.96% | -25.51% | -17.95% | -30.63% | -58.28% |
Income Before Tax | -25.53% | -19.67% | -11.49% | -17.92% | -54.43% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -25.53% | -19.67% | -11.49% | -19.31% | -54.43% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -25.53% | -19.67% | -11.49% | -19.31% | -54.43% |
EBIT | -21.96% | -25.51% | -17.95% | -30.63% | -58.28% |
EBITDA | -22.04% | -25.60% | -18.01% | -30.73% | -58.45% |
EPS Basic | -5.45% | 1.30% | 5.24% | -1.67% | 32.00% |
Normalized Basic EPS | -5.44% | -9.80% | -1.08% | -8.92% | 31.99% |
EPS Diluted | -5.45% | 1.30% | 5.24% | -1.67% | 32.00% |
Normalized Diluted EPS | -5.44% | -9.80% | -1.08% | -8.92% | 31.99% |
Average Basic Shares Outstanding | 19.04% | 21.23% | 17.64% | 17.37% | 127.09% |
Average Diluted Shares Outstanding | 19.04% | 21.23% | 17.64% | 17.37% | 127.09% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |